

Molecular Docking Study Of Cannabigerol Against Human Transient Receptors Potential: Its Role In The Management Of Pain And Fibromyalgia

Paulo Vinícius De Siqueira Santos, Jorge Veras Filho,
Brenda Siqueira Dos Santos, Francisco José Pinheiro Araújo,
Maria Júlia Dantas Pacheco Araújo Moraes,
Ohanna Louise Vasconcelos De Aquino Santos,
Rafaella Monique De Aquino Lopes Melo, Zayra Victoria De Souza Firmo,
Morgana Vital De Araújo, Ronald José Tenório Cavalcante Lames,
Alessandra Emertice De Almeida Costa, Joelmir Lucena Veiga Da Silva
Functional Practices Laboratory/ Faculty Of Medicine Of Olinda, Brazil

Abstract:

Background: Transient receptor potential (TRP) channels present role important in pain and it have been modulated phytocannabinoids. Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the cannabis plant and have presented effects on TRPV1 and TRPA1 *in vitro*. However, the CBG molecular action mechanism is not clear yet.

Materials and Methods: In this *in silico* study carried out by DockThor® program. The 3D structures of CBG (CID: 5315659), capsaicin (CID: 1548943), an TRPV1 activator, and 2-chloro-N-(4-(4-methoxyphenyl)thiazol-2-yl)-N-(3-methoxypropyl)-acetamide (JT010, CID: 18524489), an TRPA1 agonist, were downloaded from the PubChem. the human proteins targets, hTRPV1 (ID: 8GFA)23 and hTRPA1 (ID: 6PQO)24 were from the PDB database.

Results: CBG presented good binding activity in hTRPs and similar to specific ligands, capsaicin and JT010, since scores were less than - 7.0 kcal/mol. CBG formed two hydrogen bonds with TRPV1 residues and capsaicin only one bond. This binding pocket-CBG can be essential to modulate pore and desensitize/close TRPV1, suggesting ions conductance blockade and inhibiting pain stimulus. It was observed that both CBG and JT010 were docked at TRPA1 coupling domain but distinct regions and also bound to two different residues. It is suggestive that CBG be acting differently of agonist JT010, probably an desensitizer/blocker channel and may modulate pain

Conclusion: Cannabigerol interacts in human transient receptors potential and the potential binding sites that can modulate channels were identified.

Key Word: Phytocannabinoids; Cannabigerol; Transient Receptors Potential; Pain; Fibromyalgia.

Date of Submission: 10-07-2025

Date of Acceptance: 20-07-2025

I. Introduction

Transient receptor potential channels are a super family of trans-membrane ion channels involved in transduction in response to a several range of physical and chemical stimuli.¹ These channels have also been implicated as sensors of many physiological and pathological processes including itch, temperature sensation, cancers, genetic disorders, and pain.²⁻⁴ Cannabis derivatives products might have potential effects in chronic pain patients with fibromyalgia.⁵⁻⁷ TRP channels (TRPV1–4, TRPA1, and TRPM8) have been modulated by phytocannabinoids.⁸⁻¹¹

CBG is a non-psychoactive cannabinoid found in the cannabis plant. CBG converts from its acid form cannabigerolic acid, which is the principal precursor to most of the other phytocannabinoids.¹² CBG has been shown to modulate pain *in vivo* and to be the most potent inhibitor at TRPV1 and TRPM8, and to active TRPA1 *in vitro*.^{5,13-16}

Docking-based virtual screening is a structure based drug design approach widely used by the scientific community to assist drug discovery in searching for new lead compounds against relevant therapeutic

targets.^{17,18} The putative cannabidiol (CBD) binding sites in TRP channels have been identified.¹⁹⁻²¹ However, the CBG molecular action mechanism is not clear yet.

II. Material And Methods

This experimental study was carried out *in silico* approach. Molecular docking insights understand the function-structure relation in a pharmacological target and its ligand-protein binding.²²

Procedure methodology

The 3D structures of CBG (CID: 5315659), capsaicin (CID: 1548943) and 2-chloro-N-(4-(4-methoxyphenyl)thiazol-2-yl)-N-(3-methoxypropyl)-acetamide (JT010, CID: 18524489) were downloaded from the PubChem database and the human proteins hTRPV1 (ID: 8GFA)²³ and hTRPA1 (ID: 6PQO)²⁴ were from the PDB database. The channel protein and chemicals were molecularly docked by DockThor® and classified in order of highest affinity (Aff) with the channel.²² The simulations were processed from the grid center coordinates (x = 103,176, y = 103,2675 and z = 84,995) for TRPV1 and coordinates (x = 138,2465, y = -138,125 and z = 158,4815) for TRPA1 and both with 884736 total grid points. The docking poses selected and chemical interactions were visualized by UCSF Chimera version 1.14 (University of California, San Francisco, CA).

III. Results

Table no 1 shows CBG or capsaicin Aff with hTRPV1 and CBG or JT010 with hTRPA1. The Aff with hTRPV1 were - 9.0 and - 8.4 kcal/mol, and with hTRPA1 were - 7.4 and - 7.5 kcal/mol, respectively. The Aff values of hTRPV1 were lower than hTRPA1.

Table 1: Scores binding energy between CBG and chemicals with hTRPs.

Ligand	Affinity (kcal/mol)	
	hTRPV1	hTRPA1
CBG	- 9.0	- 7.4
capsaicin	- 8.9	N.D.
JT010	N.D.	- 7.5

N.D.: not determined

Spatial analyses present CBG position closed at B chain of TRPV1 (Fig. 1A and B). Similarly, capsaicin also was on B chain and CBG overlap (Fig. 1A and B).




Figure 1: 3D modeling of molecular docking between CBG (black) or capsaicin (orange) and TRPV1. A (blue), B (green), C (yellow) and D (red) chain. Side (A) and top (B) views.

However, on TRPA1 the CBG was situated between the C and D channel chains and near pore channel (Fig. 2A and B). Differently, JT010 was closed at D chain (Fig. 2A and B).




Figure 2: 3D modeling of molecular docking between CBG (black) or JT010 (cyan) and TRPA1. A (blue), B (green), C (yellow) and D (red) chain. Side (A) and top (B) views.

In the TRPV1, CBG formed hydrogen bonds with the Cys412 and Leu408 residues that presented 2.65 and 2.18 Å, respectively (Fig. 3A). While, capsaicin bonded to Tyr409 at 2.33 Å distance. Since, on the TRPA1, CBG hydrogen bonds with the Lys517 and Glu514 residues (1.99 and 1.54 Å, respectively) (Fig. 3B), while JT010 was bonded twice to Lys146 (3.04 and 1.94 Å, respectively) (data not shown).




Figure 3: Hydrogen bonds (red line) between CBG (black) or capsaicin (orange) and Cys (purple), Leu (gray) or Tyr (green) residues of TRPV1 (A) and CBG with Lys (yellow) and Glu (pink) residues of TRPA1 (B).

IV. Discussion

Interactions membrane channel-ligand modulate potential and activity cellular, hence our data present docking analyses between cannabigerol and hTRPs that could be a mechanism to pain and fibromyalgia management.

TRPV1 has been related a receptor plays an important role in certain chronic pain conditions that may be involved with fibromyalgia, such as neuropathic pain, inflammatory bowel disease and migraine.²⁵⁻²⁷ Central sensitization and upregulation of the TRPV1 signalling pathway has been observed in a murine model of fibromyalgia, indicating the direct involvement of this receptor in the pathogenesis of the disease.²⁸ TRPA1 is implicated in cold sensations related to painful stimuli.²⁹ Several studies modulating TRPA1 activity have observed that this receptor has participating in inflammatory and immune responses, and in the conversion of physical and chemical stimuli in irritative (itching) or pain sensations.³⁰⁻³³ Our data showed that CBG presented good binding activity in hTRPs, being stronger for TRPV1, and similar to specific ligands, since scores were less than - 7.0 kcal/mol.^{34,35} Molecular docking studies with CBD have also been shown its binding scores in hTRPs.^{20,21}

Structurally, TRPV channels are arranged four subunits, each with intracellular NH₂ and COOH terminal, six transmembrane helices (S1–S6), and a pore region (S5-P-S6). The pore contains a selectivity filter that, in turn, is organized by a re-entrant pore (P)-loop and small-pore helix between S5 and S6.³⁶ TRPV1 also contains an extracellular cap or turret that forms a dome above the pore's extracellular entrance, with four portals leading to the ion conductance pathway and is critical for channel function.³⁷ It was observed that both CBG and capsaicin, the canonical activator, were situated between S5 and S6 helix (Fig.1). Our data showed CBG formed two hydrogen bonds with TRPV1 residues (Cys412 and Leu408, Fig.3A), differently CBD have been bound with Asn330²¹ and capsaicin only one bond (Tyr409, Fig.3A). This binding pocket-CBG can be essential to modulate pore and desensitize/close TRPV1, suggesting ions conductance block and inhibiting pain stimulus. Since, TRPV1 is primarily expressed by small-diameter neurons of sensory ganglia, such as DRG and trigeminal ganglia.³⁶

TRPA1 possesses the NH₂ and COOH terminal parts facing the intracellular space.³⁸ The overall structure of the homotetrameric TRPA1 channel may be divided into three layers. The top layer is formed of the transmembrane domain (TMD), while the middle layer contains the coupling domain (CD) and the bottom layer consists of the ankyrin repeat domain (ARD).²⁴ We observed that both CBG and JT010, the irreversible covalent agonist, were docked at CD but distinct regions. CBG bound to TRPA1 residues, Lys517 and Glu514, while JT010 did Lys146. It is suggestive that CBG be acting differently of agonist JT010, probably an desensitizer/blocker channel and may modulate pain. CBD have been also localized at CD, but C14-polyacetylenes at ankyrin repeat domain.^{21,39} In fact, our data are related to TRPA1 that have been determined as a nociceptive channel with a plentiful presence in subpopulations of primary sensory neurons of the dorsal root, vagal and trigeminal ganglia.⁴⁰ Moreover, TRPA1 have been mainly expressed in unmyelinated C-fibers and thinly myelinated A δ -fibers, and only occasionally large myelinated fibers that were determined pain conduction pathways.⁴⁰

V. Conclusion

Cannabigerol interacts in human transient receptors potential and the potential binding sites that can modulate channels were identified.

These findings support the modulation of transient receptors potential by cannabigerol *in vitro* studies and reinforce the action of phytocannabinoids on pain and fibromyalgia management.

References

- [1]. Himmel NJ, Cox DN. Transient Receptor Potential Channels: Current Perspectives On Evolution, Structure, Function And Nomenclature. *Proc. Biol. Sci.* 2020;287:20201309.
- [2]. Caterina MJ. TRP Channel Cannabinoid Receptors In Skin Sensation, Homeostasis, And Inflammation. *ACS Chem. Neurosci.* 2014;5:1107–1116. DOI: 10.1021/Cn5000919
- [3]. Perálvarez-Marín A, Doñate-Macian P, Gaudet R. What Do We Know About The Transient Receptor Potential Vanilloid 2 (TRPV2) Ion Channel? *FEBS J.* 2012;280:5471–5487. DOI:10.1111/Febs.12302
- [4]. Vay L, Gu C, McNaughton PA. The Thermo-TRP Ion Channel Family: Properties And Therapeutic Implications. *Br. J. Pharmacol.* 2012;165:787–801. DOI:10.1111/J.1476-5381.2011.01601.X
- [5]. Van De Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, Van Velzen Moniquea. An Experimental Randomized Study On The Analgesic Effects Of Pharmaceutical-Grade Cannabis In Chronic Pain Patients With Fibromyalgia. *Pain* 2019;160(4):860-869. DOI:10.1097/J.Pain.0000000000001464
- [6]. Berger AA, Keefe J, Winnick A, Gilbert E, Eskander JP, Yazdi C, Kaye AD, Oviswanath O, Urits I. Cannabis And Cannabidiol (CBD) For The Treatment Of Fibromyalgia. *Best Practice & Research Clinical Anaesthesiology* 2020;34(3):617-631. DOI:10.1016/J.Bpa.2020.08.010.
- [7]. Khurshid H, Qureshi IA, Jahan N, Went TR, Sultan W, Sapkota A, Alfonso, M. A Systematic Review Of Fibromyalgia And Recent Advancements In Treatment: Is Medicinal Cannabis A New Hope?. *Cureus* 2021;13(8):E17332. DOI:10.7759/Cureus.17332
- [8]. De Petrocellis L, Ligresti A, Allar M, Bisogno T, Petrosino S, Et Al. Effects Of Cannabinoids And Cannabinoid-Enriched Cannabis Extracts On TRP Channels And Endocannabinoid Metabolic Enzymes. *Br. J. Pharmacol.* 2011;163:1479–1494. DOI:10.1111/J.1476-5381.2010.01166.X
- [9]. Etemad L, Karimi G, Alavi MS, Roohbakhsh A. Pharmacological Effects Of Cannabidiol By Transient Receptor Potential Channels. *Life Sciences* 2022;300:120582. DOI:10.1016/J.Lfs.2022.120582

- [10]. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, Novellis V, Di Marzo V. Non-Psychoactive Cannabinoids Modulate The Descending Pathway Of Antinociception In Anaesthetized Rats Through Several Mechanisms Of Action. *Br. J. Pharmacol.* 2011;162(3):584-596. DOI:10.1111/J.1476-5381.2010.01063.X
- [11]. Muller C, Morales P, Reggio PH. Cannabinoid Ligands Targeting TRP Channels. *Front. Mol. Neurosci.* 2019;11:487. DOI:10.3389/Fnmol.2018.00487
- [12]. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol (CBG): A Comprehensive Review Of Its Molecular Mechanisms And Therapeutic Potential. *Molecules* 2024;29. DOI:10.3390/Molecules29225471
- [13]. Li H, Ward SJ. Paclitaxel-Associated Mechanical Sensitivity And Neuroinflammation Are Sex-, Time-, And Site-Specific And Prevented Through Cannabigerol Administration In C57Bl/6 Mice. *International Journal Of Molecular Sciences* 2024;25(8):4277. DOI:10.3390/Ijms25084277
- [14]. Weerts EM, Jenkins BW, Kuang RY, Hausker A, Moore C F. Orally Administered Cannabigerol (CBG) In Rats: Cannabimimetic Actions, Anxiety-Like Behavior, And Inflammation-Induced Pain. *Pharmacology, Biochemistry, And Behavior* 2024;245:173883. DOI:10.1016/J.Pbb.2024.173883
- [15]. Rezende B, Marques KL, De Carvalho FEA Et Al. Cannabigerol Reduces Acute And Chronic Hypernociception In Animals Exposed To Prenatal Hypoxia Ischemia. *Sci. Pharm.* 2024;92:53. DOI:10.3390/Scipharm92030053
- [16]. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, Et Al. Plant-Derived Cannabinoids Modulate The Activity Of Transient Receptor Potential Channels Of Ankyrin Type-1 And Melastatin Type-8. *J. Pharmacol. Exp. Ther.* 2008;325,1007–1015. DOI:10.1124/Jpet.107.134809
- [17]. Sabe VT, Ntombela T, Jhamba LA, Maguire GEM, Govender T, Naicker T, Kruger HG. Current Trends In Computer Aided Drug Design And A Highlight Of Drugs Discovered Via Computational Techniques: A Review. *Eur. J. Med. Chem.* 2021;224. DOI:10.1016/J.Ejmech.2021.113705 113705.
- [18]. Sadybekov AV, Katritch V. Computational Approaches Streamlining Drug Discovery. *Nature* 2023;616, 673–685. DOI:10.1038/S41586-023-05905-Z.
- [19]. Muller C, Reggio PH. An Analysis Of The Putative CBD Binding Site In The Ionotropic Cannabinoid Receptors. *Front. Cell. Neurosci.* 2020;14:615811. DOI:10.3389/Fncel.2020.615811
- [20]. Silva JLV, Arruda GEJ, Mendes NN, Silva-Júnior GS, Mendes GN, Lira NBD, Aguiar ACO, Morioka CY, Costa AEA. Cannabidiol Interacts TRPA1 Channel To Promote Analgesic Effects: Docking Insights. *Br. J. Pharmacol.* 2023;180:S1,941-942. DOI:10.1111/Bph.16112
- [21]. Silva JLV, Silveira EC, Mendonça LC, Lira NBD, Correia-Neto DT, Gondim LCS, França GLAS, Morioka CY, Costa AEA. Cannabidiol Modulates TRPV1 Channel To Prevent Pain: Docking Insights. *Br. J. Pharmacol.* 2023;180:S1,1014. DOI:10.1111/Bph.16112
- [22]. Guedes IA, Silva MMP, Galheigo M, Krempser E, Magalhães CS, Barbosa HJC, Dardenne LE. DockThor-VS: A Free Platform For Receptor-Ligand Virtual Screening. *Journal Of Molecular Biology* 2024;463:168548. DOI: 0.1016/J.Jmb.2024.168548
- [23]. Neuberger A, Oda M, Nikolaev YA, Nadezhdin KD, Gracheva EO, Bagriantsev SN, Sobolevsky AI. Human TRPV1 Structure And Inhibition By The Analgesic SB-366791. *Nature Communications* 2023;14:2451. DOI: 10.1038/S41467-023-38162-9
- [24]. Suo Y, Wang Z, Zubcevic L, Hsu AL, He Q, Borgnia MJ, J RR, Lee SY. Structural Insights Into Electrophile Irritant Sensing By The Human TRPA1 Channel. *Neuron* 2020;105:882. DOI: 10.1016/J.Neuron.2019.11.023
- [25]. Gonzalez-Ramírez R. Et Al. TRP Channels And Pain, In *Neurobiology Of TRP Channels*. 2nd Edition. 2017, CRC Press/Taylor & Francis.
- [26]. O'Neill J Et Al. Unravelling The Mystery Of Capsaicin: A Tool To Understand And Treat Pain. *Pharmacol. Rev.* 2012;64(4):939–971. DOI: 10.1124/Pr.112.006163
- [27]. Alawi K, Keeble J. The Paradoxical Role Of The Transient Receptor Potential Vanilloid 1 Receptor In Inflammation. *Pharmacol. Ther.* 2010;125(2):181–195. DOI: 10.1016/J.Pharmthera.2009.10.005
- [28]. Hsiao I-H, Lin Y-W. Electroacupuncture Reduces Fibromyalgia Pain By Attenuating The HMGB1, S100B, And TRPV1 Signalling Pathways In The Mouse Brain. *Evidence-Based Complementary And Alternative Medicine* 2022;2022(1):1-13 DOI:10.1155/2022/2242074
- [29]. Hsu H-C Et Al. Electroacupuncture Reduces Fibromyalgia Pain By Downregulating The TRPV1–Perk Signalling Pathway In The Mouse Brain. *Acupuncture Med.* 2020;38(2):101–108. DOI:10.1136/Acupmed-2017-011395
- [30]. Zygmunt PM, Högestätt ED. TRPA1. *Handb Exp Pharmacol.* 2014;222:583–630. DOI: 10.1007/978-3-642-54215-2_23
- [31]. Bandell M, Story GM, Hwang SW, Et Al. Noxious Cold Ion Channel TRPA1 Is Activated By Pungent Compounds And Bradykinin. *Neuron*. 2004;41:849–857. DOI: 10.1016/S0896-6273(04)00150-3
- [32]. Kwan KY, Allchorne AJ, Vollrath MA, Et Al. TRPA1 Contributes To Cold, Mechanical, And Chemical Nociception But Is Not Essential For Hair-Cell Transduction. *Neuron*. 2006;50(2):277–289. DOI: 10.1016/J.Neuron.2006.03.042
- [33]. Viana F. TRPA1 Channels: Molecular Sentinels Of Cellular Stress And Tissue Damage. *J Physiol.* 2016;594(15):4151–4169. DOI: 10.1113/JP270935
- [34]. Liu ZL, Li L, Ma HL, Zhong QS, Ke JY, Zhang H. Mechanism Of Action Of Zhishi Daozhi Decoction In The Treatment Of Diarrhea Based On Network Pharmacology And Molecular Docking. *Drug Combination Therapy*.2023;5(1):1-8. DOI: 10.53388/DCT20230003
- [35]. Du G, Qu X, Hu J, Zhang Y, Cai Y. Identification Of Taohong Siwu Decoction In Treating Chronic Glomerulonephritis Using Network Pharmacology And Molecular Docking. *Natural Product Communications*.2022;17(11):1-12. DOI: 10.1177/1934578X2211399
- [36]. Rosenbaum T, Islas L.D. Molecular Physiology Of TRPV Channels: Controversies And Future Challenges. *Annu. Rev. Physiol.* 2023;85:293–316. DOI: 10.1146/Annurev-Physiol-030222-012349
- [37]. Yelshanskaya MV, Sobolevsky AI. Ligand-Binding Sites In Vanilloid-Subtype TRP Channels. *Front. Pharmacol.* 2022;13:900623. DOI: 10.3389/Fphar.2022.900623
- [38]. Souza Monteiro De Araujo D, Nassini R, Geppetti P, De Logu F. TRPA1 As A Therapeutic Target For Nociceptive Pain. *Expert Opinion On Therapeutic Targets* 2020;24(10):997–1008. DOI: 10.1080/14728222.2020.1815191
- [39]. Yu H, Gao D, Yang Y, Liu L, Zhao X, Na R. The Interaction Mechanism Between C14-Polyacetylene Compounds And The Rat TRPA1 Receptor: An In Silico Study. *Int. J. Mol. Sci.* 2024;25:11290. DOI: 10.3390/Ijms252011290
- [40]. Story GM, Peier AM, Reeve AJ, Et Al. ANKTM1, A TRP-Like Channel Expressed In Nociceptive Neurons, Is Activated By Cold Temperatures. *Cell* 2003;112:819–829.